Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…Abstract Number: 0354 • ACR Convergence 2022
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…Abstract Number: 1378 • ACR Convergence 2022
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…Abstract Number: 1488 • ACR Convergence 2022
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…Abstract Number: 0707 • ACR Convergence 2022
Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis
Background/Purpose: Glucocorticoids (GCs) are used commonly to treat patients with rheumatoid arthritis (RA) and other inflammatory conditions. As clinical trials are often underpowered to assess…Abstract Number: 1591 • ACR Convergence 2022
Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…Abstract Number: 0493 • ACR Convergence 2021
Hospitalization for SLE Flare Has Reduced over Two Decades in the United States: A Longitudinal Population-based Study
Background/Purpose: Longitudinal data are limited on SLE flare hospitalizations. This study aims to study longitudinal trends of SLE flare hospitalizations in the last 2 decades…Abstract Number: 0495 • ACR Convergence 2021
Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased burden of multimorbidity. Racial/ethnic disparities have also been associated with an increased burden of multimorbidity.…Abstract Number: 0561 • ACR Convergence 2021
Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports
Background/Purpose: Interstitial lung disease (ILD) is an extraarticular manifestation of RA that leads to increased morbidity and mortality. Algorithms incorporating multiple diagnostic and procedure codes…Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 15
- Next Page »
